Financial Performance - The company reported a total distributable profit of CNY 545,308,475.09 as of December 31, 2022, with a proposed cash dividend of CNY 1.00 per share, totaling CNY 40,986,221.60, which accounts for 20.36% of the net profit attributable to shareholders[6]. - In 2022, the company achieved operating revenue of CNY 1,201,316,448.76, a year-on-year increase of 27.94%[21]. - The net profit attributable to shareholders of the listed company was CNY 201,284,234.02, reflecting a growth of 32.18% compared to the previous year[21]. - The net profit after deducting non-recurring gains and losses increased by 43.17% to CNY 194,635,872.55[21]. - The net cash flow from operating activities surged by 89.17% to CNY 293,285,899.02, primarily due to increased cash receipts from sales[21]. - The company's total assets reached CNY 1,816,619,420.45, marking a 29.30% increase from the previous year[21]. - The basic earnings per share rose to CNY 0.49, a 32.43% increase year-on-year[22]. - The weighted average return on equity increased by 2.47 percentage points to 17.74%[22]. Risk Management - The company has not identified any significant risks that could materially affect its operations during the reporting period[7]. - The audit report issued by Dahua Certified Public Accountants confirmed the financial statements' accuracy and completeness, providing a standard unqualified opinion[5]. - The company has implemented a risk control system to enhance operational efficiency and risk management[163]. Product Development and Innovation - The company implemented a "micro-innovation" management initiative, resulting in over 700 proposals and cost savings exceeding CNY 1 million[30]. - The company is focusing on enhancing its product pipeline and brand strategy following the successful restructuring of Dechangxiang, which is expected to contribute positively to future profitability[36]. - The company aims to leverage new policies supporting traditional Chinese medicine to drive innovation and development in the pharmaceutical sector[38]. - The company is developing new products through collaborations with several renowned research institutions, focusing on traditional Chinese medicine modernization[83]. - The company is conducting exploratory new drug development for a proprietary Chinese medicine formula aimed at treating children's purpura[85]. - The company is focusing on the research and development of new products aimed at treating various ailments, including lung heat cough and kidney inflammation[87]. Market Expansion and Sales Strategy - The company expanded its sales team from over 700 to nearly 1,100 by the end of December 2022, enhancing its grassroots market penetration[34]. - The company aims to strengthen its marketing system while expanding its presence in secondary and tertiary terminal channels to improve market share[47]. - The company is actively expanding its OTC sales channels and third terminals to mitigate the impact of price reductions due to national medical reform and strict cost control measures[119]. - The company has expanded its online channels and is exploring the pharmaceutical e-commerce sector, partnering with Alibaba Health Pharmacy and JD Health Pharmacy[114]. Research and Development - Research and development expenses rose to CNY 17,862,876.35, a significant increase of 132.55% compared to the previous year[58]. - The company's R&D investment accounted for 1.49% of operating revenue during the reporting period[94]. - The company invested a total of 1,492.82 million RMB in research and development projects, with a significant increase in the research on the "Ancient Classic Prescription - Qiji Shenkang Granules" by 1,492.82% compared to the previous year[95]. Environmental Responsibility - The company has established a wastewater treatment plant with a capacity of 100 tons per day, achieving COD and ammonia nitrogen removal rates exceeding 98%[168]. - The company has committed to not transferring or managing shares held prior to the IPO for 36 months from the listing date[187]. - The company reduced carbon emissions by 158 tons through various technological upgrades in 2022[182]. Corporate Governance - The company held a total of 4 shareholder meetings in 2022, with all resolutions passed successfully[126]. - The total pre-tax remuneration for directors and senior management amounted to 520.63 million CNY in 2022[128]. - The company has established a comprehensive performance evaluation system for senior management, linking their performance directly to compensation[160]. Future Outlook - The company plans to continue its strategic initiatives and market expansion efforts in the upcoming year[125]. - The company aims to enhance management efficiency and expand sales channels in 2023, focusing on "micro-innovation" for operational improvements[112]. - The company is committed to ongoing research to ensure the efficacy and safety of its products, particularly in the context of traditional Chinese medicine[88].

Financial Performance - The company's operating revenue for Q3 2022 was ¥280,350,016.75, representing an increase of 18.09% compared to the same period last year[7]. - The net profit attributable to shareholders for Q3 2022 was ¥39,648,056.50, a decrease of 6.79% year-on-year[7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥34,150,910.59, down 11.54% from the previous year[7]. - The basic earnings per share for Q3 2022 was ¥0.09, reflecting a decline of 13.46% compared to the same period last year[10]. - Total operating revenue for Q3 2022 reached ¥710,137,900.69, an increase of 15.6% compared to ¥614,376,129.90 in Q3 2021[25]. - Net profit for Q3 2022 was ¥95,398,331.00, a decrease of 14.1% from ¥110,939,844.61 in Q3 2021[28]. - The net profit attributable to the parent company shareholders for the first three quarters of 2022 is CNY 103,639,947.24, compared to CNY 111,924,172.61 in the same period of 2021, reflecting a decrease of approximately 7.9%[31]. - The basic and diluted earnings per share for the current period are both CNY 0.25, down from CNY 0.27 in the previous year[34]. Assets and Liabilities - The total assets at the end of Q3 2022 amounted to ¥1,606,923,327.51, an increase of 21.68% from the end of the previous year[10]. - Total assets as of September 30, 2022, were ¥1,606,923,327.51, compared to ¥1,404,991,334.54 at the end of 2021, indicating a growth of 14.4%[25]. - Total liabilities as of September 30, 2022, amounted to ¥465,730,217.77, an increase from ¥372,926,361.05 at the end of 2021, reflecting a rise of 24.8%[25]. - Shareholders' equity as of September 30, 2022, was ¥1,141,193,109.74, compared to ¥1,032,064,973.49 at the end of 2021, representing an increase of 10.6%[25]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥141,348,018.36, down 5.28% compared to the previous year[10]. - Cash inflows from operating activities totaled CNY 807,693,128.37, an increase from CNY 700,340,919.21 in the same period last year, representing a growth of approximately 15.4%[34]. - Cash outflows from operating activities amounted to CNY 666,345,110.01, compared to CNY 551,115,243.00 in the previous year, showing an increase of about 20.9%[34]. - The net cash flow from operating activities is CNY 141,348,018.36, a decrease from CNY 149,225,676.21 in the same period last year, reflecting a decline of approximately 5.9%[34]. - The net cash flow from investing activities is CNY -172,718,691.54, compared to CNY 6,410,432.53 in the previous year, indicating a significant decline in cash flow from investments[36]. - Cash inflows from financing activities totaled CNY 100,145,623.77, slightly down from CNY 104,920,000.00 in the previous year[36]. - The net cash flow from financing activities is CNY -13,894,382.73, compared to CNY -102,065,833.73 in the previous year, showing an improvement in cash flow management[36]. - The ending cash and cash equivalents balance is CNY 498,953,218.99, down from CNY 503,621,016.75 at the end of the previous year[36]. Operational Insights - The company reported a decrease in operating income due to reduced other income and investment income[12]. - The company has expanded its sales channels, contributing to the increase in operating revenue[12]. - The company has received government subsidies related to specific projects amounting to ¥6,578,211.66 in Q3 2022[10]. - Total operating costs for Q3 2022 were ¥609,551,080.98, up from ¥511,897,328.63 in Q3 2021, reflecting a year-over-year increase of 19.1%[25]. - Research and development expenses in Q3 2022 amounted to ¥11,265,704.67, significantly higher than ¥2,557,036.22 in Q3 2021, indicating a year-over-year increase of 339.5%[28]. - Cash and cash equivalents as of September 30, 2022, were ¥498,953,218.99, down from ¥544,218,274.90 at the end of 2021, representing a decrease of 8.3%[23]. - Accounts receivable increased to ¥292,140,103.48 as of September 30, 2022, compared to ¥256,673,012.56 at the end of 2021, reflecting a growth of 13.8%[23]. - Inventory as of September 30, 2022, was ¥141,189,038.45, up from ¥88,567,082.81 at the end of 2021, marking an increase of 59.4%[23].

Financial Performance - Guizhou Sanli reported a revenue of 500 million RMB for the first half of 2022, representing a year-on-year increase of 15%[16]. - The company's net profit for the same period was 80 million RMB, up 10% compared to the previous year[16]. - The company's operating revenue for the first half of the year reached ¥429,787,883.94, representing a 14.01% increase compared to ¥376,980,719.84 in the same period last year[24]. - Net profit attributable to shareholders decreased by 7.78% to ¥63,991,890.74 from ¥69,388,454.18 year-on-year[24]. - The net profit after deducting non-recurring gains and losses increased by 8.39% to ¥61,079,477.61 compared to ¥56,352,001.92 in the previous year[24]. - The net cash flow from operating activities was ¥77,357,428.57, down 8.35% from ¥84,403,441.29 in the same period last year[24]. - The company's total assets increased by 9.58% to ¥1,539,590,523.29 from ¥1,404,991,334.54 at the end of the previous year[24]. - Basic earnings per share decreased by 5.88% to ¥0.16 from ¥0.17 year-on-year[24]. - The weighted average return on net assets decreased by 0.94 percentage points to 6.00% from 6.94% in the previous year[24]. - The company reported a total of 14,403,914.98 million yuan in revenue for the first half of 2022, reflecting a growth compared to the previous period[67]. Market Expansion and Product Development - User data indicates a growth in customer base by 20%, reaching 1 million active users[16]. - The company plans to launch three new products in the second half of 2022, focusing on herbal medicine and OTC drugs[16]. - Guizhou Sanli aims to expand its market presence in Southeast Asia, targeting a 25% increase in international sales by the end of 2023[16]. - The company is focusing on expanding its core product line and exploring new products as part of its "14th Five-Year Plan" strategy[46]. - The company’s core product, the Kaohoujian spray (children's type), has covered 323 cities and 1,856 counties, reaching over 152,000 various terminals, including more than 5,000 grade hospitals and over 104,000 retail terminals[40]. Research and Development - The company has allocated 50 million RMB for R&D in new technologies and product development[16]. - Research and development expenses surged by 419.92% to approximately ¥2.46 million, compared to ¥473,240.09, reflecting increased investment in R&D[53]. - The company has established long-term strategic partnerships with multiple research institutions and universities to enhance product quality and safety[38]. Quality Control and Production Management - The company has established a comprehensive quality control system in accordance with the new GMP certification, ensuring strict adherence to production quality management standards[34]. - The company emphasizes continuous quality checks during production, including self-inspection, mutual inspection, and specialized inspections by the quality assurance department[34]. - The company has implemented a standardized production process with specific technical standards and operational procedures to enhance production management[34]. - The company has a dual supplier strategy for raw materials to ensure stable supply and mitigate risks[34]. Financial Management and Investments - The company completed the bankruptcy reorganization of its subsidiary, Dechangxiang, in May 2022, integrating it into the consolidated financial statements[51]. - The company proposed over 300 process optimizations through its "micro-innovation" initiative, resulting in cost savings of over ¥400,000[48]. - The company has increased its external equity investment by RMB 240.48 million compared to the previous year[61]. - The company reported a net investment income of CNY 7,220,817.91, a decrease from CNY 16,293,342.25 in the previous year, indicating a decline of approximately 55.7%[163]. Environmental Responsibility - The company has established a wastewater treatment plant with a capacity of 100 tons per day, achieving COD and ammonia nitrogen removal rates exceeding 98%[81]. - The company operates two natural gas boilers, which are equipped with dust capture and exhaust gas absorption devices, ensuring emissions meet national standards[81]. - The company has received environmental impact assessment approvals for multiple production lines, including a 60 million bottle spray production line and a 500 million capsule production line, both in normal production[84]. - The company actively responds to national carbon neutrality initiatives by using energy-saving equipment and clean energy such as natural gas, aiming to reduce carbon emissions[97]. Shareholder and Corporate Governance - The company held its annual shareholders' meeting on May 19, 2022, where all proposals were approved[74]. - The company has committed to not transferring or entrusting the management of its shares for 36 months from the date of its stock listing[100]. - The company will ensure compliance with regulations regarding related party transactions to protect shareholder interests[114]. - The largest shareholder, Zhang Hai, holds 188,668,440 shares, representing 45.92% of the total shares, with 70,000,000 shares pledged[137].

证券代码：603439 证券简称：贵州三力 编号：2022-035 贵州三力制药股份有限公司 关于"2021年度业绩说明会暨投资者集体接待日活动" 举办情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 贵州三力制药股份有限公司（以下简称"公司"）于2022年5月13日参加了 贵州证监局、贵州证券业协会联合深圳市全景网络有限公司举办的2021年度业绩 说明会暨投资者集体接待日活动（以下简称"活动"），就投资者关心的公司经 营业绩、财务状况、发展战略规划等事项与投资者进行了沟通和交流，现将有关 事项公告如下： 一、本次活动举办情况 本次活动于2022年5月13日09:30-11:30在"全景路演"(http://rs.p5w.net) 举办。关于本次活动的举办事项，公司于2022年5月6日在上海证券交易所网站披 露了《贵州三力制药股份有限公司关于举办"2021年度业绩说明会暨投资者集体 接待日活动"的公告》(2022-030)。 公司董事长、总经理张海先生，公司董事、董事会秘书张千帆先生，公司董 事、财务总监张红玉女士参 ...

证券代码：603439 证券简称：贵州三力 公告编号：2022-030 贵州三力制药股份有限公司 关于举办"2021年度业绩说明会暨投资者集体接待日 活动"的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为促进上市公司规范运作、健康发展，增强上市公司信息透明度，加强与广 大投资者沟通交流，进一步提升投资者关系管理水平，贵州证监局、贵州证券业 协会联合深圳市全景网络有限公司，将于 2022 年 5 月 13 日 09:30-11:30 在"全 景路演"(http://rs.p5w.net)举办"2021 年度贵州辖区上市公司业绩说明会暨 投资者集体接待日活动"。 出席本次活动人员有: 公司董事长暨总经理张海先生、董事会秘书张千帆先 生、财务总监张红玉女士。 为充分尊重投资者、提升交流的针对性,现就公司本次活动提前向投资者公 开征集问题 , 广 泛 听 取 投 资 者 的 意 见 和 建 议 。 投 资 者 可 即 日 起 访 问 https://ir.p5w.net/zj/，进入问题征集专题页面提交问题。公司将在会 ...

Financial Performance - The company's revenue for Q1 2022 was ¥158,680,694.88, representing a year-on-year increase of 22.86%[6] - The net profit attributable to shareholders was ¥23,729,640.91, showing a slight increase of 1.23% compared to the same period last year[6] - The net profit after deducting non-recurring gains and losses was ¥21,148,537.90, reflecting a decrease of 4.54% compared to the previous year[6] - The total net profit attributable to the parent company was 23,729,640.91, compared to 23,440,996.58 in the previous period, showing a slight increase[35] - The net profit for the current period was 19,979,984.26, down from 23,440,948.04, representing a decrease of approximately 14.5%[32] - The operating profit decreased to 24,345,225.45 from 28,247,559.38, reflecting a decline of about 13.4%[32] - The total profit for the current period was 24,279,274.85, compared to 27,877,559.38 in the previous period, reflecting a decrease of about 12.5%[32] Cash Flow - The net cash flow from operating activities reached ¥55,434,729.44, marking a significant increase of 92.25% year-on-year[6] - Cash flow from operating activities increased to 55,434,729.44, compared to 28,834,794.90 in the previous period, indicating a growth of approximately 92.5%[39] - Cash inflow from investment activities was 48,843,199.90, down from 190,453,478.56, a decrease of about 74.4%[40] - The cash flow from financing activities showed a net inflow of 825,000.00, compared to a net outflow of 2,175,000.00 in the previous period[40] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,442,860,297.55, up 2.70% from the end of the previous year[9] - Total assets as of March 31, 2022, were ¥1,442,860,297.55, compared to ¥1,404,991,334.54 at the end of 2021, reflecting a growth of 2.7%[24] - Total liabilities increased to ¥387,035,173.68 from ¥372,926,361.05, marking a rise of 3.0%[25] - The company's equity attributable to shareholders rose to ¥1,055,658,009.91 from ¥1,031,458,113.76, an increase of 2.3%[25] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 46,987[11] - The top shareholder, Zhang Hai, holds 45.92% of the shares, amounting to 188,668,440 shares, which are pledged[14] Research and Development - Research and development expenses in Q1 2022 amounted to ¥1,024,157.45, significantly higher than ¥88,525.76 in Q1 2021, indicating a focus on innovation[30] Other Financial Metrics - The weighted average return on equity decreased by 0.45 percentage points to 1.91%[9] - The company reported non-recurring gains totaling ¥2,581,103.01, primarily from investment income[10] - The company's cash and cash equivalents decreased to ¥454,854,470.68 from ¥544,218,274.90 year-over-year, a decline of 16.4%[20] - Accounts receivable decreased to ¥230,483,634.07 from ¥256,673,012.56, representing a reduction of 10.2%[20] - Inventory increased to ¥118,949,165.16 from ¥88,567,082.81, showing a growth of 34.3% year-over-year[20] - The total comprehensive income attributable to the parent company was 23,729,640.91, slightly higher than 23,440,996.58 from the previous period[35] - The basic and diluted earnings per share remained stable at 0.06[35] - The total cash and cash equivalents at the end of the period were 454,854,470.68, down from 523,683,798.04, a decrease of approximately 13.1%[40]

Acquisitions and Investments - The company acquired 95% of Guizhou Dechangxiang Pharmaceutical Co., Ltd. for CNY 232 million to fulfill obligations under a restructuring plan[6] - The company participated in an auction for assets of Guizhou Dechangxiang, winning equipment and inventory for CNY 88.18 million[6] - The company plans to invest over 50% of its audited net assets in the GMP Phase II project and future industrial layout in 2022[7] - The company initiated the construction of the GMP Phase II project, aiming to enhance the level of intelligent manufacturing in traditional Chinese medicine[41] - The company is actively pursuing upstream and downstream integration, including establishing a Chinese medicinal herb production base to ensure raw material supply[148] Financial Performance - The company's operating revenue for 2021 was CNY 938,966,120.18, representing a 48.99% increase compared to CNY 630,224,958.06 in 2020[26] - Net profit attributable to shareholders for 2021 was CNY 152,282,553.77, a 62.08% increase from CNY 93,952,848.26 in 2020[26] - The net cash flow from operating activities increased by 145.13% to CNY 155,037,459.58 in 2021, compared to CNY 63,247,318.18 in 2020[26] - The company's total assets at the end of 2021 were CNY 1,404,991,334.54, an 11.61% increase from CNY 1,258,791,072.80 at the end of 2020[26] - The company’s net assets attributable to shareholders at the end of 2021 were CNY 1,031,458,113.76, reflecting a 5.05% increase from CNY 981,892,812.45 at the end of 2020[26] Risk Management and Compliance - There are no significant risks that could materially affect the company's operations during the reporting period[11] - The company has no non-operating fund occupation by controlling shareholders or related parties[9] - The company has no violations in decision-making procedures for providing guarantees[11] - The company emphasizes the importance of investor awareness regarding potential risks in forward-looking statements[8] - The company emphasized compliance and internal control improvements, enhancing risk management through audits and external checks[43] Research and Development - The company invested approximately ¥50 million in the development of new traditional Chinese medicine formulations based on ancient classic prescriptions[102] - The company is conducting systematic research on its flagship product, the children's version of the throat spray, with a focus on quality standard enhancement and clinical evaluation[102] - The company has established partnerships with several universities and research institutions to enhance its R&D capabilities[102] - The company is focusing on the development of new products aimed at treating chronic throat inflammation and oral ulcers, with ongoing research for both adult and children's formulations[110] - The company has reported no pesticide residue in the materials and formulations of its products, ensuring safety and compliance with health standards[110] Marketing and Sales Strategy - The company expanded its marketing network, adding over 340 new first-tier medical institutions and over 6,000 grassroots medical institutions[39] - The sales model has shifted towards a professional academic promotion model, which has become the mainstream approach in the pharmaceutical manufacturing industry[56] - The company plans to expand its market presence by strengthening the development of secondary and tertiary terminal channels, aiming to increase its overall industry position and market share[59] - The company is focusing on academic collaborations with hospitals and universities to strengthen its product value and market presence[148] - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million yuan allocated for potential deals[175] Management and Governance - The total pre-tax remuneration for the management team amounted to 5,204,800 CNY, with significant increases in shareholdings for several executives due to stock incentives[171] - The company has a strategic focus on stock incentives to enhance executive performance and align interests with shareholders[171] - The company plans to maintain its current management structure through May 2024, ensuring stability in leadership during this period[167] - The company has a structured compensation management system in place for its directors and senior management[183] - The company has undergone several board meetings throughout 2021, with all resolutions passed unanimously[186] Industry Outlook - The pharmaceutical manufacturing industry in China is expected to maintain steady growth due to increasing healthcare demands driven by rising living standards, the three-child policy, and an aging population[147] - The company anticipates challenges from national procurement policies that may pressure major enterprises to transform and upgrade[147] - The company recognizes the potential risks from policy changes in the pharmaceutical industry, which could impact its operational model and product competitiveness[153] - The company is facing risks related to product price reductions due to stricter national medical reform policies and the implementation of volume-based procurement, which are expected to lead to inevitable price declines in the future[156] - The company plans to enhance its marketing efforts, accelerate new product development, and strengthen external collaborations to mitigate risks associated with product concentration and market competition[155]

Financial Performance - Revenue for Q3 2021 reached ¥237,395,410.06, an increase of 190.73% compared to the same period last year[7] - Net profit attributable to shareholders was ¥42,535,718.43, reflecting a significant increase of 1,859.03% year-over-year[7] - The net profit after deducting non-recurring gains and losses was ¥38,605,714.48, up 1,643.93% from the previous year[7] - Total operating revenue for the first three quarters of 2021 reached ¥614,376,129.90, a significant increase of 69.0% compared to ¥363,575,605.42 in the same period of 2020[35] - Operating profit for the first three quarters of 2021 was ¥132,320,566.82, compared to ¥59,092,098.10 in the previous year, reflecting a growth of 124.0%[39] - Net profit for the first three quarters of 2021 was ¥110,939,844.61, an increase of 128.0% from ¥48,647,750.25 in the same period of 2020[39] - Basic earnings per share for the first three quarters of 2021 were ¥0.27, compared to ¥0.12 in the previous year, representing a 125.0% increase[41] Cash Flow - Cash flow from operating activities for the year-to-date was ¥149,225,676.21, showing a growth of 289.25%[10] - The net cash flow from operating activities was $149,225,676.21, a significant increase from $38,336,632.26 in the previous period, representing a growth of approximately 288%[44] - Total cash inflow from investment activities amounted to $341,551,553.08, while cash outflow was $335,141,120.55, resulting in a net cash flow of $6,410,432.53, compared to a negative cash flow of $254,840,959.59 previously[44] - Cash inflow from financing activities totaled $104,920,000.00, a decrease from $461,508,377.83 in the prior period, leading to a net cash flow of -$102,065,833.73 compared to a positive cash flow of $338,387,290.10 previously[46] - The company reported a total cash and cash equivalents balance of $503,621,016.75 at the end of the period, up from $361,497,841.88 at the end of the previous period, indicating an increase of approximately 39%[46] - The company experienced a net increase in cash and cash equivalents of $53,570,275.01, down from $121,882,962.77 in the previous period, indicating a decrease of approximately 56%[46] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,320,622,214.38, a 4.91% increase from the end of the previous year[10] - The total liabilities of the company as of September 30, 2021, were RMB 327,435,655.83, up from RMB 276,913,804.86, which is an increase of approximately 18.2%[33] - The company's total equity reached RMB 993,186,558.55, compared to RMB 981,877,267.94 at the end of 2020, showing a growth of about 1.3%[33] - As of September 30, 2021, the company's total current assets reached RMB 1,011,688,137.68, an increase from RMB 920,014,015.00 at the end of 2020, representing a growth of approximately 9.96%[30] Expenses - Total operating costs amounted to ¥511,897,328.63, up 67.7% from ¥305,114,484.43 year-over-year[35] - Sales expenses increased to ¥296,237,668.59, up 84.5% from ¥160,548,444.59 year-over-year[35] - Tax expenses for the first three quarters of 2021 were ¥5,804,917.85, an increase of 73.8% compared to ¥3,339,624.70 in the same period of 2020[35] - Cash paid to employees increased to $54,989,161.64 from $30,533,609.19, reflecting an increase of about 80%[44] - Cash paid for taxes rose to $74,058,230.50 from $48,718,643.98, marking an increase of approximately 52%[44] - Cash outflow for other operating activities was $298,910,053.53, up from $169,949,518.23, representing an increase of about 76%[44] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 30,053[17] - The company’s net profit attributable to shareholders was RMB 328,075,497.69, compared to RMB 317,981,879.08 at the end of 2020, reflecting an increase of about 3.4%[33] Other Information - The company reported non-recurring gains of ¥4,530,000.00 from government subsidies related to tax incentives and R&D projects[10] - The increase in revenue and profit was attributed to the recovery of main business operations following the impact of the pandemic in the previous year[16] - The company has not reported any new product launches or significant market expansion strategies during this period[34] - Research and development expenses for the first three quarters of 2021 were ¥2,557,036.22, slightly down from ¥2,942,667.08 in the same period of 2020[35] - Investment income for the first three quarters of 2021 was ¥21,141,896.97, compared to ¥1,191,957.63 in the previous year, indicating a substantial increase[39] - Accounts receivable increased to RMB 234,390,209.93 from RMB 225,458,026.13, reflecting a growth of approximately 3.9%[26] - Inventory levels rose significantly to RMB 84,126,278.26, compared to RMB 47,507,666.54 at the end of 2020, marking an increase of around 77.2%[30] - The company reported a decrease in short-term borrowings to RMB 180,000,000.00 from RMB 200,000,000.00, a reduction of 10%[30] - The company’s other current liabilities increased to RMB 299,781.33 from RMB 766,312.59, indicating a decrease of approximately 60.9%[33]

Financial Performance - The company reported a total revenue of 150 million CNY for the first half of 2021, representing a year-on-year increase of 20%[15]. - Net profit attributable to shareholders reached 30 million CNY, up 15% compared to the same period last year[15]. - The gross profit margin improved to 60%, an increase of 5 percentage points from the previous year[15]. - The company's operating revenue for the first half of the year reached ¥376,980,719.84, representing a year-on-year increase of 33.72% compared to ¥281,919,480.70 in the same period last year[21]. - Net profit attributable to shareholders was ¥69,388,454.18, up 49.29% from ¥46,478,078.79 in the previous year[21]. - The net cash flow from operating activities increased significantly by 90.62%, totaling ¥84,403,441.29 compared to ¥44,277,543.84 in the same period last year[21]. - Basic earnings per share rose to ¥0.17, reflecting a 41.67% increase from ¥0.12 in the previous year[21]. - The company's total assets decreased by 2.10% to ¥1,232,331,507.51 from ¥1,258,791,072.80 at the end of the previous year[21]. - The company’s net assets attributable to shareholders decreased by 3.30% to ¥949,450,712.63 from ¥981,892,812.45 at the end of the previous year[21]. - The weighted average return on net assets increased to 6.94%, up 0.77 percentage points from 6.17% in the previous year[21]. Market Expansion and Product Development - User data indicated a growth in active customers by 25%, totaling 500,000 users by the end of June 2021[15]. - The company plans to launch two new products in Q3 2021, aiming to capture an additional 10% market share in the herbal medicine sector[15]. - Future outlook includes an expected revenue growth of 15% for the full year 2021, driven by new product launches and market expansion strategies[15]. - The company has expanded its distribution network by 40%, reaching new regions across China[15]. - The company has adjusted its product planning to include new dosage forms such as pills, ointments, and granules, preparing for future product line expansion[67]. - The company has established a new marketing subsidiary, Sanli Zhongyue, to enhance its sales coverage and improve the effectiveness of its marketing network[68]. - The company has expanded its product offerings, including the production and sales of Western and Chinese medicines, disinfectants, and medical devices[87]. Research and Development - Research and development expenses increased by 30% to 10 million CNY, focusing on innovative drug formulations[15]. - The company is actively collaborating with research institutions to improve product quality standards and conduct in-depth studies on raw materials[51]. - The company has implemented a dynamic production planning process based on market demand to maximize production efficiency[39]. - The company is conducting large-scale resource surveys of medicinal materials to optimize the quality standards of its products[51]. - The company has established a comprehensive quality control system and has passed the new GMP certification, ensuring strict adherence to production quality management standards[43]. Environmental and Social Responsibility - The company has established a wastewater treatment plant with a capacity of 100 tons per day, achieving a COD and ammonia nitrogen removal rate of over 98%[108]. - The company has implemented online monitoring equipment for wastewater, which is connected to provincial and municipal platforms for real-time data transmission[114]. - The company has successfully guided the planting of medicinal herbs over 2,040 acres in the Pingba District, resulting in an annual income of 6,000 yuan for 296 impoverished households, achieving complete poverty alleviation[115]. - In the Zongdi Township, the company has guided the planting of medicinal herbs over 800 acres, increasing the average annual income of farmers from 3,200 yuan to 5,300 yuan, also achieving complete poverty alleviation[115]. - The company is classified as a key pollutant discharge unit and complies with national environmental protection laws and regulations, ensuring that emissions meet standards[104]. - The company has received no administrative penalties for environmental issues during the reporting period[114]. Governance and Shareholder Structure - The actual controller and major shareholders, including Zhang Hai, committed to a 36-month lock-up period for their shares following the company's IPO[119]. - The company has ensured compliance with commitments regarding non-competition and related party transactions, with Zhang Hai affirming no current or future competition with the company's business[131]. - The company has a long-term commitment from its major shareholders and executives to not transfer or manage their shares during the lock-up period[122]. - The company has established a mechanism for shareholders to report any changes in their shareholdings, ensuring transparency[126]. - The company has outlined specific conditions under which the lock-up period may be extended, particularly if the stock price falls below the issue price[130]. - The company has committed to maintaining a competitive edge by ensuring that its major shareholders do not engage in competing businesses[132]. - The company has a clear strategy for managing potential conflicts of interest among its executives and shareholders[131]. - The company has received commitments from its board members and senior management to adhere to the same share transfer restrictions as major shareholders[127]. - The company has established a framework for prioritizing the purchase of any competing assets or businesses that may arise from its major shareholders[132]. - The company has a robust governance structure in place to ensure compliance with all commitments made by its shareholders and executives[131]. Risks and Challenges - The company faced a risk of reduced drug prices due to the ongoing centralized procurement of pharmaceuticals across various regions[93]. - The company is focusing on risk management strategies to mitigate potential impacts from regulatory changes in the pharmaceutical industry[93]. - The report does not provide specific future guidance or performance outlook for the upcoming quarters[176]. - The company has no major litigation or arbitration matters during the reporting period[154]. - The company and its controlling shareholder, Zhang Hai, have not engaged in any dishonest activities during the reporting period[154].

Financial Performance - The company achieved a net profit attributable to shareholders of RMB 93,952,848.26 for the year 2020, with a year-end distributable profit of RMB 318,546,950.49[8] - The proposed cash dividend is RMB 2.50 per 10 shares, totaling RMB 101,830,554.00, which represents 31.97% of the company's undistributed profits and 108.38% of the net profit for 2020[8] - The company's operating revenue for 2020 was CNY 630.22 million, a decrease of 28.69% compared to 2019[31] - Net profit attributable to shareholders was CNY 93.95 million, down 29.40% from the previous year[31] - The net cash flow from operating activities was CNY 63.25 million, a decline of 45.59% year-on-year[31] - The company's net assets increased by 50.81% year-on-year, reaching CNY 981.89 million by the end of 2020[31] - Total assets grew by 72.25% to CNY 1.26 billion compared to the end of 2019[31] - Basic earnings per share for 2020 were CNY 0.24, a decrease of 33.33% from 2019[31] - The weighted average return on equity was 10.98%, down 11.79 percentage points from the previous year[31] Operational Challenges - The decline in revenue was primarily attributed to the impact of the COVID-19 pandemic on production and academic promotion[34] - The company focused on internal control management and performance assessment to improve operational efficiency during the pandemic[87] - The COVID-19 pandemic has caused operational challenges, but the company is focusing on marketing, R&D innovation, and project construction to mitigate risks[200] Risk Management - The company has detailed potential risks in its operations and corresponding countermeasures in the report[12] - The company has confirmed that there are no non-operating fund occupations by controlling shareholders or related parties[10] - The company has not violated decision-making procedures for providing guarantees[12] Market Position and Strategy - The company is positioned to benefit from the ongoing healthcare reforms and increased government focus on the pharmaceutical industry, particularly in traditional Chinese medicine[66] - The company has established long-term strategic partnerships with multiple research institutions and universities to enhance product quality and safety, focusing on new product development and quality standard improvements[72] - The company plans to strengthen its marketing network and improve service quality through the integration and expansion of existing sales personnel[64] - The company is actively involved in revising local medicinal material standards, particularly for the Baizhu Jinlong herb, enhancing its competitive edge in the market[72] Product Development and R&D - The company is conducting extensive research on the distribution and storage of medicinal materials across various regions, ensuring a stable supply chain for its products[72] - The company is enhancing the production technology and quality standards of its existing products, including the "Kaitoujian Spray" for both adults and children[142] - The company is actively pursuing the modernization of traditional Chinese medicine through extensive new drug research and development[135] - The company is conducting systematic research on its flagship product, the "Kaitoujian Spray (Children's Type)," which includes quality standard enhancements and is set to be included in the 2020 edition of the Chinese Pharmacopoeia[138] - The company is focusing on the development of new drugs for pediatric purpura diseases, filling a gap in the market for traditional Chinese medicine products[135] Investment and Acquisitions - The company invested RMB 111.90 million to acquire a 25.64% stake in Hanfang Pharmaceutical, which was completed on December 21, 2020[70] - The company plans to enhance product reserves and increase profit growth points through acquisitions of mature drugs and production licenses[190] - The company’s investment in Guizhou Hanfang Pharmaceutical is a strategic move to enhance its market presence[171] Marketing and Sales - The company has established a strong marketing system through specialized academic promotion services[160] - The company’s marketing expenses accounted for 77.83% of total sales expenses, amounting to 215,398,103 CNY[161] - The company plans to establish a self-built marketing network to strengthen market control and improve sales management capabilities[194] Compliance and Quality Control - The company has implemented a comprehensive quality control system in compliance with the new GMP standards, ensuring product quality throughout the production process[57] - The risk of being removed from the National Essential Drug List is low due to the company's adherence to GMP standards and the prioritization of pediatric medications in national insurance policies[199] Future Outlook - The pharmaceutical industry is undergoing significant transformation due to policy changes, with a focus on professionalization and internet integration[192] - The company intends to expand its qualifications and establish an academic brand through high-quality publications and academic activities[195] - In 2021, the company will focus on developing traditional Chinese medicine and enhancing product quality and user experience[189]